Innate Pharma Dividends and Buybacks
Dividend criteria checks 0/6
Innate Pharma does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.1%
Buyback Yield
| Total Shareholder Yield | -0.1% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)
Oct 24
Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price
May 21Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 24Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Dec 21Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher
Sep 30Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates
Sep 16Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Jun 09News Flash: Analysts Just Made A Massive Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts
Mar 30Rainbows and Unicorns: Innate Pharma S.A. (EPA:IPH) Analysts Just Became A Lot More Optimistic
Dec 18Does Innate Pharma (EPA:IPH) Have A Healthy Balance Sheet?
Sep 27Innate Pharma S.A. (EPA:IPH) Analysts Are Reducing Their Forecasts For This Year
Aug 04Industry Analysts Just Made A Dazzling Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts
May 12Industry Analysts Just Made A Captivating Upgrade To Their Innate Pharma S.A. (EPA:IPH) Revenue Forecasts
Apr 13Time To Worry? Analysts Just Downgraded Their Innate Pharma S.A. (EPA:IPH) Outlook
Mar 26Is Innate Pharma (EPA:IPH) Weighed On By Its Debt Load?
Nov 11Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if IPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IPH's dividend payments have been increasing.
Dividend Yield vs Market
| Innate Pharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (IPH) | n/a |
| Market Bottom 25% (FR) | 2.1% |
| Market Top 25% (FR) | 5.5% |
| Industry Average (Biotechs) | 1.6% |
| Analyst forecast (IPH) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate IPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate IPH's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IPH has not reported any payouts.